Tags

Type your tag names separated by a space and hit enter

Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study.
J Gastroenterol Hepatol. 2020 May 13 [Online ahead of print]JG

Abstract

BACKGROUND AND AIM

The prospective, open-label, randomized study aims to compare the efficacy of lansoprazole, a fast orally disintegrating proton pump inhibitor (PPI), and dexlansoprazole, a dual delayed release PPI, in patients with atypical symptoms of gastroesophageal reflux disease (GERD).

METHODS

Patients with atypical GERD symptoms with a total reflux symptom index score > 10 were eligible for enrollment. From February 2018 to December 2019, 232 subjects were randomly assigned (1:1 ratio) to receive oral lansoprazole, Takepron OD 30 mg, once daily before breakfast or oral dexlansoprazole, Dexilant 60 mg, once daily before breakfast for 8 weeks. The primary end-point is to compare the symptoms response rate after an 8-week PPI therapy between the two groups.

RESULTS

There were 232 study subjects enrolling in this study. After the 8-week PPI therapy, dexlansoprazole-treated group had a significantly higher response rate than lansoprazole-treated group in cough (76.5% vs 38.0%) and globus (69.7% vs 30.8%) (P all < 0.05 by intention-to-treat). Multivariate logistic regression analysis showed that the use of dexlansoprazole, presence of dyslipidemia, and typical GERD symptoms (acid reflux and heartburn) were predictors for symptom response for cough; the use of dexlansoprazole and presence of erosive esophagitis were predictors for symptom response for globus (P all < 0.05). No predictor for therapy response to hoarseness was noted.

CONCLUSIONS

There is a higher response rate for cough and globus symptoms in patients with atypical GERD after the 8-week PPI therapy with dexlansoprazole rather than lansoprazole.

Authors+Show Affiliations

Department of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan. Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. Department of Medicine, National Yang-Ming University Hospital, Yilan, Taiwan.Department of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan. Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. Keelung Hospital, Ministry of Health and Welfare, Keelung, Taiwan.Department of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan. Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.Department of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan. Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.Department of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan. Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.Department of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan. Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.Department of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan. Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32401385

Citation

Lin, Xi-Hsuan, et al. "Comparison of the Efficiency of Two Different Proton Pump Inhibitor Formula in Treatment of Patients With Atypical Gastroesophageal Reflux Disease: a Prospective Randomized Study." Journal of Gastroenterology and Hepatology, 2020.
Lin XH, Luo JC, Ting PH, et al. Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study. J Gastroenterol Hepatol. 2020.
Lin, X. H., Luo, J. C., Ting, P. H., Chang, T. E., Huang, Y. H., Hou, M. C., & Lee, F. Y. (2020). Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.15093
Lin XH, et al. Comparison of the Efficiency of Two Different Proton Pump Inhibitor Formula in Treatment of Patients With Atypical Gastroesophageal Reflux Disease: a Prospective Randomized Study. J Gastroenterol Hepatol. 2020 May 13; PubMed PMID: 32401385.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study. AU - Lin,Xi-Hsuan, AU - Luo,Jiing-Chyuan, AU - Ting,Po-Hsiang, AU - Chang,Tien-En, AU - Huang,Yi-Hsiang, AU - Hou,Ming-Chih, AU - Lee,Fa-Yauh, Y1 - 2020/05/13/ PY - 2020/01/20/received PY - 2020/05/02/revised PY - 2020/05/07/accepted PY - 2020/5/14/pubmed PY - 2020/5/14/medline PY - 2020/5/14/entrez KW - GERD (gastroesophageal reflux disease) KW - cough KW - dexlansoprazole KW - globus KW - hoarseness JF - Journal of gastroenterology and hepatology JO - J. Gastroenterol. Hepatol. N2 - BACKGROUND AND AIM: The prospective, open-label, randomized study aims to compare the efficacy of lansoprazole, a fast orally disintegrating proton pump inhibitor (PPI), and dexlansoprazole, a dual delayed release PPI, in patients with atypical symptoms of gastroesophageal reflux disease (GERD). METHODS: Patients with atypical GERD symptoms with a total reflux symptom index score > 10 were eligible for enrollment. From February 2018 to December 2019, 232 subjects were randomly assigned (1:1 ratio) to receive oral lansoprazole, Takepron OD 30 mg, once daily before breakfast or oral dexlansoprazole, Dexilant 60 mg, once daily before breakfast for 8 weeks. The primary end-point is to compare the symptoms response rate after an 8-week PPI therapy between the two groups. RESULTS: There were 232 study subjects enrolling in this study. After the 8-week PPI therapy, dexlansoprazole-treated group had a significantly higher response rate than lansoprazole-treated group in cough (76.5% vs 38.0%) and globus (69.7% vs 30.8%) (P all < 0.05 by intention-to-treat). Multivariate logistic regression analysis showed that the use of dexlansoprazole, presence of dyslipidemia, and typical GERD symptoms (acid reflux and heartburn) were predictors for symptom response for cough; the use of dexlansoprazole and presence of erosive esophagitis were predictors for symptom response for globus (P all < 0.05). No predictor for therapy response to hoarseness was noted. CONCLUSIONS: There is a higher response rate for cough and globus symptoms in patients with atypical GERD after the 8-week PPI therapy with dexlansoprazole rather than lansoprazole. SN - 1440-1746 UR - https://www.unboundmedicine.com/medline/citation/32401385/Comparison_of_the_efficiency_of_two_different_proton_pump_inhibitor_formula_in_treatment_of_patients_with_atypical_gastroesophageal_reflux_disease:_a_prospective_randomized_study L2 - https://doi.org/10.1111/jgh.15093 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.